PRRT2 Mutation and Serum Cytokines in Paroxysmal Kinesigenic Dyskinesia

Abstract

Objective

Paroxysmal kinesigenic dyskinesia (PKD) is a rare movement disorder PRRT2 gene mutations have been reported to cause PKD. However, the pathophysiological mechanism of PKD remains unclear, and it is unknown whether an inflammatory response is involved in the occurrence of this disease. We aimed to investigate the symptomatology, genotype, and serum cytokines of patients with PKD.

Methods

We recruited 21 patients with PKD, including 7 with familial PKD and 14 with sporadic PKD. Their clinical features were investigated, and blood samples were collected, and PRRT2 mutations and cytokine levels were detected.

Results

The mean age at PKD onset was 12.3±2.2 years old. Dystonia was the most common manifestation of dyskinesia, and the limbs were the most commonly affected parts. All attacks were induced by identifiable kinesigenic triggers, and the attack durations were brief (<1 min). Four different mutations from 9 probands were identified in 7 familial cases (71.4%) and 14 sporadic cases (28.6%). Two of these mutations (c.649dupC, c.620_621delAA) had already been reported, while other 2 (c.1018_1019delAA, c.1012+1G>A) were previously undocumented. The tumor necrosis factor (TNF)-α level in the PKD group was significantly higher than that in the age- and sex-matched control group (P=0.025). There were no significant differences in the interleukin (IL)-1β, IL-2R, IL-6, IL-8, or IL-10 levels between the two groups.

Conclusion

In this study, we summarized the clinical and genetic characteristics of PKD. We found that the serum TNF-α levels were elevated in patients clinically diagnosed with PKD, suggesting that an inflammatory response is involved in the pathogenesis of PKD.

Keywords

paroxysmal kinesigenic dyskinesia / proline-rich transmembrane protein 2 / cytokines

References

[1] Ebrahimi-FakhariD, SaffariA, WestenbergerA, et al.. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain, 2015, 138: 3476-3495 Pt 12

[2] ChenWJ, LinY, XiongZQ, et al.. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet, 2011, 43(12): 1252-1255

[3] de VriesEE, van den MunckhofB, BraunKP, et al.. Inflammatory mediators in human epilepsy: A systematic review and meta-analysis. Neurosci Biobehav Rev, 2016, 63: 177-190

[4] IoriV, FrigerioF, VezzaniA. Modulation of neuronal excitability by immune mediators in epilepsy. Curr Opin Pharmacol, 2016, 26: 118-123

[5] BrunoMK, HallettM, Gwinn-HardyK, et al.. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology, 2004, 63(12): 2280-2287

[6] McGuireS, ChanchaniS, KhuranaDS. Paroxysmal Dyskinesias. Semin Pediatr Neurol, 2018, 25: 75-81

[7] GallentineWB, ShinnarS, HesdorfferDC, et al.. Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury. Epilepsia, 2017, 58(6): 1102-1111

[8] KureS. Atypical Thomsen’s disease. Tokyo Igakukai Zasshi, 1892, 6: 505-514

[9] LampertiC, InvernizziF, SolazziR, et al.. Clinical and genetic features of paroxysmal kinesigenic dyskinesia in Italian patients. Eur J Paediatr Neurol, 2016, 20(1): 152-157

[10] ErroR, SheerinUM, BhatiaKP. Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. Mov Disord, 2014, 29(9): 1108-1116

[11] McGovernEM, RozeE, CounihanTJ. The expanding spectrum of paroxysmal movement disorders: update from clinical features to therapeutics. Curr Opin Neurol, 2018, 31(4): 491-497

[12] MéneretA, GrabliD, DepienneC, et al.. PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology, 2012, 79(2): 170-174

[13] GroffenAJ, KlapwijkT, van RootselaarAF, et al.. Genetic and phenotypic heterogeneity in sporadic and familial forms of paroxysmal dyskinesia. J Neurol, 2013, 260(1): 93-99

[14] CaoL, HuangX-J, ZhengL, et al.. Identification of a novel PRRT2 mutation in patients with paroxysmal kinesigenic dyskinesias and c.649dupC as a mutation hot-spot. Parkinsonism Relat Disord, 2012, 18(5): 704-706

[15] OnoS, YoshiuraK, KinoshitaA, et al.. Mutations in PRRT2 responsible for paroxysmal kinesigenic dyskinesias also cause benign familial infantile convulsions. J Hum Genet, 2012, 57(5): 338-341

[16] MaoCY, ShiCH, SongB, et al.. Genotype-phenotype correlation in a cohort of paroxysmal kinesigenic dyskinesia cases. J Neurol Sci, 2014, 340(1–2): 91-93

[17] HuangXJ, WangSG, GuoXN, et al.. The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China. Mov Disord, 2020, 35(8): 1428-1437

[18] LiHF, NiW, XiongZQ, et al.. PRRT2 c.649dupC mutation derived from de novo in paroxysmal kinesigenic dyskinesia. CNS Neurosci Therap, 2013, 19(1): 61-65

[19] ZhaoG, LiuX, ZhangQ, et al.. PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures. Int J Neurosci, 2018, 128(8): 751-760

[20] GardellaE, BeckerF, MollerRS, et al.. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol, 2016, 79(3): 428-436

[21] YinXM, LinJH, CaoL, et al.. Familial paroxysmal kinesigenic dyskinesia is associated with mutations in the KCNA1 gene. Hum Mol Genet, 2018, 27(4): 625-637

[22] LangenbruchL, BiskupS, YoungP, et al.. Two mutations in the nicotinic acetylcholine receptor subunit A4 (CHRNA4) in a family with autosomal dominant sleep-related hypermotor epilepsy. Epileptic Disord, 2020, 22(1): 116-119

[23] TianWT, HuangXJ, MaoX, et al.. Proline-rich transmembrane protein 2-negative paroxysmal kinesigenic dyskinesia: Clinical and genetic analyses of 163 patients. Mov Disord, 2018, 33(3): 459-467

[24] LiW, WangY, LiB, et al.. 16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability. Brain Behav, 2018, 8(11): e01134

[25] ColemanJ, JouannotO, RamakrishnanSK, et al.. PRRT2 Regulates Synaptic Fusion by Directly Modulating SNARE Complex Assembly. Cell Rep, 2018, 22(3): 820-831

[26] ValenteP, CastroflorioE, RossiP, et al.. PRRT2 Is a Key Component of the Ca(2+)-Dependent Neurotransmitter Release Machinery. Cell Rep, 2016, 15(1): 117-131

[27] MoJ, WangB, ZhuX, et al.. PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by influencing synaptic function in the primary motor cortex of rats. Neurobiol Dis, 2019, 121: 274-285

[28] BeattieEC, StellwagenD, MorishitaW, et al.. Control of synaptic strength by glial TNFalpha. Science, 2002, 295(5563): 2282-2285

[29] StellwagenD, BeattieEC, SeoJY, et al.. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci, 2005, 25(12): 3219-3228

[30] StellwagenD, MalenkaRC. Synaptic scaling mediated by glial TNF-alpha. Nature, 2006, 440(7087): 1054-1059

[31] WheelerD, KnappE, BandaruVV, et al.. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem, 2009, 109(5): 1237-1249